Opinion|Videos|November 16, 2026

Balancing Benefit and Toxicity With Lurbinectedin Maintenance in the IMforte Era

Panelists examine the addition of lurbinectedin to atezolizumab as first-line maintenance therapy for extensive-stage small cell lung cancer.

Panelists examine the addition of lurbinectedin to atezolizumab as first-line maintenance therapy for extensive-stage small cell lung cancer. This follows positive results showing improved progression-free and overall survival in a setting where earlier cytotoxic maintenance strategies had failed. They weigh the survival benefit against added toxicities such as myelosuppression and fatigue, and describe how patient age, fitness, and treatment goals inform whether the regimen is offered. The conversation centers on shared decision-making, including how clinicians help patients recognize when the burden of ongoing therapy outweighs its benefit, even without disease progression. Faculty share their approach to continuing maintenance while it is tolerated, the potential future role of circulating tumor DNA in guiding de-escalation, and the option of stepping back to immunotherapy alone. They also reflect on the tension of adding cytotoxic therapy for patients who may already be achieving durable disease control with an immune checkpoint inhibitor alone.


Related to this article